JUN 07, 2021 7:00 AM PDT

COVID Test Results in a Second?

WRITTEN BY: Tara Fernandez

Scientists have developed a handheld diagnostic device, capable of detecting the presence of the SARS-CoV-2’s spike protein in just one second. The new, ultra-rapid testing technology is powered by microfluidics and contains antibodies specific to the viral protein. The study was published in the Journal of Vacuum Science and Technology.

When it comes to accurate testing, the PCR test is considered the gold standard. However, the trade-off is that this test requires specialized users, equipment, and facilities, all of which lengthen processing times. Rapid testing methods that can be done on the go could help catch positive cases sooner and limit the chances of spreading to complement global vaccination efforts.

“This could alleviate slow COVID-19 testing turnaround time issues,” said Minghan Xian, one of the device’s creators.

The researchers had previously demonstrated how their technology could be used to detect disease biomarkers for conditions such as Zika virus infections, cerebral spinal fluid leaks, and even heart attacks.

According to Xian, the core of the device contains a disposable biosensor strip, similar to those in commercially available glucose monitors for managing diabetes. “Within the microfluidic channel, a few electrodes are exposed to fluid. One is coated with gold, and COVID-relevant antibodies are attached to the gold surface via a chemical method,” Xian explained.

What makes the device unique is the ability to amplify the signals from minute amounts of viral protein present in a biological sample, a trait that enables both the speed and precision of the innovation.

“Our sensor system, a circuit board, uses a transistor to amplify the electrical signal, which then gets converted into a number on the screen,” said Xian. “The magnitude of this number depends on the concentration of antigen, the viral protein, present within our test solution.” 

 


Sources: Journal of Vacuum Science and Technology, AIP Publishing.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
APR 20, 2021
Clinical & Molecular DX
Stressed Out Pregnant Mothers More Likely to Have Girls
APR 20, 2021
Stressed Out Pregnant Mothers More Likely to Have Girls
Scientists from the University of Granada used hair samples to monitor cortisol in a cohort of over 100 pregnant women a ...
JUN 22, 2021
Clinical & Molecular DX
See the Nasties on Your Skin with Your Smartphone
JUN 22, 2021
See the Nasties on Your Skin with Your Smartphone
The skin is home to around 1.5 trillion bacteria, which together with fungi and viruses, make up the skin microbiota. Th ...
AUG 10, 2021
Drug Discovery & Development
Epidemiology and postexposure prophylaxis of rabies virus
AUG 10, 2021
Epidemiology and postexposure prophylaxis of rabies virus
Rabies is a viral disease that can be transmitted from an infected animal to another animal or human. In the U ...
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 16, 2021
Clinical & Molecular DX
Your T-Shirt Could Soon Tell You if Your Heart Is Ok
SEP 16, 2021
Your T-Shirt Could Soon Tell You if Your Heart Is Ok
Forget uncomfortable chest straps or clunky wristbands—thanks to a new innovation in nanotechnology, your t-shirt ...
SEP 20, 2021
Cancer
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
SEP 20, 2021
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
For the past several decades, cancer antigen 125 (CA 125), a protein located on the surface of ovarian cancer cells, has ...
Loading Comments...